Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash from Investing Activities: 2019-2025

Historic Cash from Investing Activities for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $41.8 million.

  • IDEAYA Biosciences' Cash from Investing Activities rose 308.46% to $41.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.6 million, marking a year-over-year increase of 92.91%. This contributed to the annual value of -$502.6 million for FY2024, which is 217.16% down from last year.
  • Per IDEAYA Biosciences' latest filing, its Cash from Investing Activities stood at $41.8 million for Q3 2025, which was down 9.04% from $45.9 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Cash from Investing Activities high stood at $79.8 million for Q1 2025, and its period low was -$354.0 million during Q1 2024.
  • For the 3-year period, IDEAYA Biosciences' Cash from Investing Activities averaged around -$44.9 million, with its median value being $23.5 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 2,388.14% in 2022, then surged by 374.83% in 2023.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Cash from Investing Activities stood at -$413,000 in 2021, then slumped by 2,388.14% to -$10.3 million in 2022, then slumped by 989.36% to -$111.9 million in 2023, then plummeted by 76.08% to -$197.1 million in 2024, then surged by 308.46% to $41.8 million in 2025.
  • Its last three reported values are $41.8 million in Q3 2025, $45.9 million for Q2 2025, and $79.8 million during Q1 2025.